BIOATLA, INC. Interest Expense
BIOATLA, INC. (BCAB) reported Interest Expense of $0 for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-23.
Discontinued › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2023-03-23
- BIOATLA, INC. interest expense for the quarter ending 2021-12-31 was $0.00, a 100.00% decline year-over-year.
- BIOATLA, INC. interest expense for the quarter ending 2021-09-30 was $0.00, a 100.00% decline year-over-year.
- BIOATLA, INC. interest expense for the quarter ending 2021-06-30 was $1.00K, a 99.87% decline year-over-year.
- BIOATLA, INC. interest expense for the quarter ending 2021-03-31 was $2.00K, a 99.63% decline year-over-year.
- BIOATLA, INC. interest expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- BIOATLA, INC. interest expense for fiscal 2021 was $3.00K, a 99.78% decline from fiscal 2020.
- BIOATLA, INC. interest expense for fiscal 2020 was $1.39M, a 14.79% decline from fiscal 2019.
- BIOATLA, INC. interest expense for fiscal 2019 was $1.63M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-03-23 | |||
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $0.00 derived: sum of 2 quarters · filed 2023-03-23 | $1.00K derived: sum of 3 quarters · filed 2023-03-23 | $3.00K 10-K · filed 2023-03-23 |
| 2021-09-30 | $0.00 10-Q · filed 2021-11-15 | $1.00K derived: sum of 2 quarters · filed 2022-08-09 | $3.00K 10-Q · filed 2022-11-04 | $5.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-06-30 | $1.00K 10-Q · filed 2022-08-09 | $3.00K 10-Q · filed 2022-08-09 | $5.00K derived: sum of 3 quarters · filed 2022-08-09 | $91.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $2.00K 10-Q · filed 2022-05-05 | $4.00K derived: sum of 2 quarters · filed 2022-05-05 | $90.00K derived: sum of 3 quarters · filed 2022-05-05 | $844.00K derived: sum of 4 quarters · filed 2022-05-05 |
| 2020-12-31 | $2.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $88.00K derived: sum of 2 quarters · filed 2022-02-28 | $842.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.39M 10-K · filed 2022-02-28 |
| 2020-09-30 | $86.00K 10-Q · filed 2021-11-15 | $840.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.39M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $754.00K 10-Q · filed 2021-08-13 | $1.30M 10-Q · filed 2021-08-13 | ||
| 2020-03-31 | $547.00K 10-Q · filed 2021-05-12 | |||
| 2019-12-31 | $1.63M 10-K · filed 2022-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |